@maughanonc
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
I am a physician specializing in the treatment of genitourinary cancers. I am passionate for improving cancer therapy through research.
Salt Lake City, UT
Joined February 2017
- Tweets1.4K
- Following580
- Followers1.5K
- Likes2.5K
Benjamin L Maughan retweeted
Our @JAMAOnc view point is now in print.
@VivekSubbiah and I argue that the traditional TNM staging, while important, no longer reflects the biology of cancer, and we propose a framework and a path forward to implement a change.
Check it out - and share some thoughts.
Benjamin L Maughan retweeted
Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!
Benjamin L Maughan retweeted
Happy birthday, Emily Wang! Your ideas for reaching patients are so thoughtful. We're glad to have you on our Clinical Advisory Board. I hope today you’re the one who feels connected and celebrated by everyone around you!
Benjamin L Maughan retweeted
In this Cancer Interviews conversation with Bruce Morton, Andrew shares his experience with kidney cancer, treatment, and life today. youtube.com/watch?v=8Z9sM4Of…
Watch the full interview, and explore more of Andrew’s perspective through his recent patient stories on the KCA website!
Benjamin L Maughan retweeted
🎉Beyond thrilled to have joined and to be working with the incredible @DrChoueiri et al @DanaFarber!
A very special thank you to @montypal for his tremendous mentorship and support! And many thanks to all the other mentors who have helped me along the way 🙏
😅 Looking back as a PGY-14, it only took two internal medicine residencies, a few research years, and an oncology fellowship to get here. But I enjoyed every bit of the journey and met so many incredible people!!
@UniversiteEge @YaleIMed @UTMDAnderson @cityofhope @IMG_Oncologists @ASCOTECAG @ASCO @DanaFarber_GU @ConquerCancerFd @kureit @kidneycan @KidneyCancer
I’m looking forward to the KIM-1 data further helping here. Pre-op vs post-op? Also ctDNA story isn’t finished. Newer methods have higher sensitivity so might be useful?
Five years later, KEYNOTE-564 is no longer just a DFS story.
Adjuvant pembrolizumab shows durable DFS and OS benefit in high-risk kidney cancer.
Now precision matters: can we better identify who needs treatment and who does not?
@OncoAlert @OpenMedicineHQ @Uromigos
Benjamin L Maughan retweeted
Five years later, KEYNOTE-564 is no longer just a DFS story.
Adjuvant pembrolizumab shows durable DFS and OS benefit in high-risk kidney cancer.
Now precision matters: can we better identify who needs treatment and who does not?
@OncoAlert @OpenMedicineHQ @Uromigos
🆕 Article in press: Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study
@DrChoueiri, @tompowles1
🔗doi.org/10.1016/j.annonc.202…
Benjamin L Maughan retweeted
“Natural or chemical?”
Daraxonrasib: C₄₄H₅₈N₈O₅S.
Also chemical:
Water: H₂O.
Oxygen: O₂.
Vitamin C: C₆H₈O₆.
The real question is not natural vs chemical.
It is: does it work, and is it safe?
Benjamin L Maughan retweeted
Dolly Parton's name is in the funding acknowledgments of a 2020 NEJM paper on mRNA-1273, right next to NIAID 🎶
🔬 $1M in April 2020, which paid for the assay that first showed the vaccine was generating an immune response
🧬 Another $1M in 2022 for pediatric infectious disease, including infections in kids with cancer
📚 332 million free children’s books since 1995
🏔️ approx 9 million into Sevier County after the 2016 Gatlinburg fires
"I just see a need and if I can fill it, then I will." 💕
#Tennessee #MedTwitter #DollyParton
Dolly Parton left a mark on science, public health and education. She donated to medical centres, vaccine research, and disaster relief, and had one of the most famous animals in science named after her: Dolly, the cloned sheep. Scientists are paying tribute to her. go.nature.com/4xoOKAT
Benjamin L Maughan retweeted
Working Group 4 introduces updated terminology for advanced #ProstateCancer. @AarmstrongDuke @DukeCancer sits down with @neerajaiims @huntsmancancer to discuss the Prostate Cancer Working Group 4 consensus criteria and updated disease nomenclature. Dr. Armstrong explains that the terms castration-sensitive and castration-resistant have been replaced by androgen pathway modulator naive, sensitive, and resistant, applicable to any treatment, not just ADT. #WatchNow > bit.ly/4fud78e
Benjamin L Maughan retweeted
📺 We spoke with Dr. Brad McGregor of @DanaFarber on the results of the phase 2 RADICAL trial on radium-223 + #cabozantinib for patients with #RCC and bone metastases, and how the role of bone-directed therapies continue to improve outcomes for patients with metastatic disease: buff.ly/BFPYBF5
Benjamin L Maughan retweeted
ENZAMET at 8 years shows the early benefit persists vs nonsteroidal antiandrogen
⏳ Median OS 7.9 vs 5.8 yr, HR 0.73
📊 8-yr clinical PFS 43% vs 20%
🛡️ Deaths from other causes 78 vs 76, no excess
🛡️ Falls were more frequent (0.70 vs 0.24 per 100 person-yr).
Why this matters for your practice: 💡 the comparator is a first-generation NSAA, so this does not re-rank first-line choices. It does give the maturest long-term safety read on an ARPI in mHSPC.
Congrats to @ChrisSweens1 and huge team, recognition for this longterm effort
#ProstateCancer #mHSPC #GUonc
Benjamin L Maughan retweeted
💜 Learn the Facts
Testicular cancer is most common in younger men, but it can occur at any age.
Know your body. Pay attention to changes. If something doesn’t feel normal, talk with a healthcare provider.
Learn more: testicularcancerawarenessfou…
#TesticularCancer
Benjamin L Maughan retweeted
fda.gov/news-events/press-an…
Daraxonrasib just approved! No words can explain the impact and the hope this brings to our patients fighting pancreatic cancer!
Benjamin L Maughan retweeted
In 2002, Daniel Kahneman received the prize in economic sciences – not as an economist, but as a psychologist.
His groundbreaking work brought psychological insight into economics, challenging the idea that humans are purely rational decision-makers.
In his bestselling book 'Thinking, Fast and Slow', Kahneman breaks down how we think using two systems:
System 1 – fast, intuitive, emotional
System 2 – slow, deliberate, logical
He revealed how systematic cognitive biases – not just emotions – shape our everyday decisions. From money and risk to leadership and policy, his research changed how we understand human behaviour.
This book didn’t just explain the mind – it reshaped economics, finance, healthcare, and public policy.
Read more: nobelprize.org/prizes/econom…
ALT Portrait of Daniel Kahneman, smiling with arms crossed, standing outdoors with blurred greenery in the background.
Benjamin L Maughan retweeted
A special moment at our USPCC conference when the FDA approval for Pluvicto in APMS occurred mid conference. Congratulation to the study leaders- our friends and mentors @sartor_oliver @DrScottTagawa and Michael Morris, and congratulations to @novartis and to the patients and staff who made this study a success.
Benjamin L Maughan retweeted
High-risk prostate cancer is not one disease.
GETUG-AFU 18 supports local intensification in N0 disease.
STAMPEDE supports systemic intensification in a higher-risk population.
In the PSMA-PET era, are we still treating the same “high-risk” disease?
@TheLancetOncol @GETUG_Unicancer @PaulSargos @OncoAlert @ONCOassist @OpenMedicineHQ @APCCC_Lugano
Benjamin L Maughan retweeted
📺 We recently spoke with @maughanonc of @UTMDAnderson about the OMNIVORE trial and its updated long-term follow-up findings in metastatic #RCC: buff.ly/tiMtpcl
🔎 Patients who achieve an objective response to #nivolumab may experience durable treatment-free intervals after immunotherapy discontinuation, while sequential salvage #ipilimumab demonstrated limited benefit.
Benjamin L Maughan retweeted
1/5 Our study on panitumumab-based EGFR blockade in renal medullary carcinoma (RMC) is out in Clinical Cancer Research: aacrjournals.org/clincancerr… #MsaouelLab, #endRMC #kidneycancer
